We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

Fintel reports that on June 2, 2025, JP Morgan downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Neutral. Analyst Price Forecast Suggests 0.02% Downside As of ...

Sanofi to acquire Blueprint Medicines for about $9.1B The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. Analyst Price Forecast Suggests 0.05% Upside As of June 2, 2025 ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotechnology company specializing in precision therapies for cancer and rare diseases, has been making significant strides in the ...